ADS-ADEA 2015* Jana Parkanyiova
Eli Lilly Australia, NSW, Australia
Presentations this author is a contributor to:
LY2963016 Insulin Glargine (LY IGlar) Compared with Lantus® Insulin Glargine (IGlar) in Patients with Type 1 Diabetes Mellitus (T1DM): Efficacy, Safety, and Patient-reported Outcomes from the ELEMENT-1 Study (#46)
11:45 AM
Julio Rosenstock
ADS Clinical Orals: Type 1 Diabetes
LY2963016 Insulin Glargine (LY IGlar) Compared with Lantus® Insulin Glargine (IGlar) in Patients with Type 2 Diabetes Mellitus (T2DM): Efficacy, Safety, and Patient-reported Outcomes from the ELEMENT-2 Study (#164)
3:30 PM
Julio Rosenstock
ADS Clinical Orals: Therapies for Type 2 Diabetes